未知生产厂商
BAL0891 is SillaJen's next-generation cancer candidate and a first-in-class anti-cancer drug that simultaneously inhibits TTK and PLK1, two proteins involved in cancer cell division. It has been granted U.S. FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML) and is currently in a global Phase 1 trial in patients with solid tumors and blood cancers.
BAL0891 is SillaJen's next-generation cancer candidate and a first-in-class anti-cancer drug that simultaneously inhibits TTK and PLK1, two proteins involved in cancer cell division. It has been granted U.S. FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML) and is currently in a global Phase 1 trial in patients with solid tumors and blood cancers.
